Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAP2K4 | P45985 | 1/20 | 0.41 |
| ▸ | RORC | P51449 | 4/20 | 0.37 |
| ▸ | RARG | P13631 | 1/20 | 0.37 |
| ▸ | STK17B | O94768 | 1/20 | 0.36 |
| ▸ | STK17A | Q9UEE5 | 1/20 | 0.36 |
| ▸ | RPS6KA5 | O75582 | 1/20 | 0.36 |
| ▸ | CKS1B | P61024 | 2/20 | 0.35 |
| ▸ | SKP1 | P63208 | 2/20 | 0.35 |
| ▸ | SKP2 | Q13309 | 2/20 | 0.35 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.35 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.35 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.35 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.35 |
| ▸ | PPARG | P37231 | 1/20 | 0.35 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.34 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.34 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.34 |
| ▸ | HSP90AB1 | P08238 | 1/20 | 0.34 |
| ▸ | CCNK | O75909 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30725494 | 1.00 | MAP2K4 (0.41) | MAP2K4RORCRARGSTK17BSTK17A | |
| SCHEMBL22911971 | 0.80 | PIM1 (0.50) | STK17BSTK17ARPS6KA5L3MBTL1HSP90AA1 | |
| SCHEMBL29595692 | 0.80 | PIM1 (0.50) | STK17BSTK17ARPS6KA5L3MBTL1HSP90AA1 | |
| SCHEMBL7016168 | 0.77 | L3MBTL1 (0.44) | MAP2K4CHRM2CHRM4CHRM1CHRM3 | |
| SCHEMBL19100171 | 0.74 | RPS6KA5 (0.41) | RPS6KA5KDM4ECDK9 | |
| SCHEMBL19100608 | 0.74 | MAP2K4 (0.43) | MAP2K4RORCCHRM2CHRM4CHRM1 | |
| SCHEMBL29057628 | 0.74 | MAP2K4 (0.50) | MAP2K4RORCKDM4EALDH1A1CYP11B2 | |
| SCHEMBL8216089 | 0.73 | ELANE (0.52) | MAP2K4CHRM2CHRM4CHRM1CHRM3 | |
| SCHEMBL30725430 | 0.72 | STK17B (0.39) | STK17BSTK17ARPS6KA5CKS1BSKP1 | |
| SCHEMBL29174599 | 0.72 | STK17B (0.39) | STK17BSTK17ARPS6KA5CKS1BSKP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 27 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-117430589-A | 2-aminopyrimidine compound or salt thereof, and preparation method and application thereof | 励缔(杭州)医药科技有限公司 | 2024-01-23 | — | — | CN | disclosed |
| EP-3057956-B1 | POLYCYCLIC INHIBITORS OF CYCLIN-DEPENDENT KINASE 7 (CDK7) | DANA FARBER CANCER INST INC (US) | 2021-05-05 | — | — | EP | disclosed |
| EP-3057956-B1 | POLYCYCLIC INHIBITORS OF CYCLIN-DEPENDENT KINASE 7 (CDK7) | DANA FARBER CANCER INST INC (US) | 2021-05-05 | — | — | EP | disclosed |
| US-20210061803-A1 | INHIBITORS OF CYCLIN-DEPENDENT KINASE 7 (CDK7) | SYROS PHARMACEUTICALS INC (US) | 2021-03-04 | — | — | US | disclosed |
| US-20210061803-A1 | INHIBITORS OF CYCLIN-DEPENDENT KINASE 7 (CDK7) | SYROS PHARMACEUTICALS INC (US) | 2021-03-04 | — | — | US | disclosed |
| US-10906889-B2 | Polycyclic inhibitors of cyclin-dependent kinase 7 (CDK7) | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2021-02-02 | — | — | US | disclosed |
| US-10906889-B2 | Polycyclic inhibitors of cyclin-dependent kinase 7 (CDK7) | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2021-02-02 | — | — | US | disclosed |
| US-10865206-B2 | Inhibitors of cyclin-dependent kinase 7 (CDK7) | SYROS PHARMACEUTICALS, INC. (US) | 2020-12-15 | — | — | US | disclosed |
| US-10865206-B2 | Inhibitors of cyclin-dependent kinase 7 (CDK7) | SYROS PHARMACEUTICALS, INC. (US) | 2020-12-15 | — | — | US | disclosed |
| CN-105849099-B | Polycyclic inhibitors of cyclin dependent kinase 7(CDK7) | 达纳-法伯癌症研究所股份有限公司 | 2020-01-17 | — | — | CN | disclosed |
| US-20170327496-A1 | INHIBITORS OF CYCLIN-DEPENDENT KINASE 7 (CDK7) | OXFORD FINANCE LLC, AS COLLATERAL AGENT | 2017-11-16 | — | — | US | disclosed |
| US-20170327496-A1 | INHIBITORS OF CYCLIN-DEPENDENT KINASE 7 (CDK7) | OXFORD FINANCE LLC, AS COLLATERAL AGENT | 2017-11-16 | — | — | US | disclosed |
| US-20160264554-A1 | POLYCYCLIC INHIBITORS OF CYCLIN-DEPENDENT KINASE 7 (CDK7) | DANA-FARBER CANCER INSTITUTE, INC. | 2016-09-15 | — | — | US | disclosed |
| US-20160264554-A1 | POLYCYCLIC INHIBITORS OF CYCLIN-DEPENDENT KINASE 7 (CDK7) | DANA-FARBER CANCER INSTITUTE, INC. | 2016-09-15 | — | — | US | disclosed |
| US-20160264554-A1 | POLYCYCLIC INHIBITORS OF CYCLIN-DEPENDENT KINASE 7 (CDK7) | DANA-FARBER CANCER INSTITUTE, INC. | 2016-09-15 | — | — | US | disclosed |
| EP-3057956-A1 | POLYCYCLIC INHIBITORS OF CYCLIN-DEPENDENT KINASE 7 (CDK7) | Dana-Farber Cancer Institute, Inc. (US) | 2016-08-24 | — | — | EP | disclosed |
| WO-2016058544-A1 | INHIBITORS OF CYCLIN-DEPENDENT KINASE 7 (CDK7) | SYROS PHARMACEUTICALS, INC. (US) | 2016-04-21 | — | — | WO | disclosed |
| WO-2016058544-A1 | INHIBITORS OF CYCLIN-DEPENDENT KINASE 7 (CDK7) | SYROS PHARMACEUTICALS, INC. (US) | 2016-04-21 | — | — | WO | disclosed |
| WO-2015058140-A1 | POLYCYCLIC INHIBITORS OF CYCLIN-DEPENDENT KINASE 7 (CDK7) | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2015-04-23 | — | — | WO | disclosed |
| WO-2015058140-A1 | POLYCYCLIC INHIBITORS OF CYCLIN-DEPENDENT KINASE 7 (CDK7) | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2015-04-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10906889-B2 | Polycyclic inhibitors of cyclin-dependent kinase 7 (CDK7) | CDK13, CDK3, CDK12 | MAP2K4 68/4885RORC 536/4885RARG 3015/4885 |
| US-20160264554-A1 | POLYCYCLIC INHIBITORS OF CYCLIN-DEPENDENT KINASE 7 (CDK7) | CDK13, CDK3, CDK12 | MAP2K4 68/4885RORC 536/4885RARG 3015/4885 |
| US-20170327496-A1 | INHIBITORS OF CYCLIN-DEPENDENT KINASE 7 (CDK7) | CDK7, CDK3, CDK9 | MAP2K4 72/4885RORC 348/4885RARG 2180/4885 |
| US-20210061803-A1 | INHIBITORS OF CYCLIN-DEPENDENT KINASE 7 (CDK7) | CDK7, CDK3, CDK9 | MAP2K4 72/4885RORC 348/4885RARG 2180/4885 |
| US-10865206-B2 | Inhibitors of cyclin-dependent kinase 7 (CDK7) | CDK7, CDK3, CDK9 | MAP2K4 72/4885RORC 348/4885RARG 2180/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.